Chong Kun Dang "Napabeltan Shows Positive Interim Results in Phase 2 COVID-19 Treatment Trial"

[Asia Economy Reporter Cho Hyun-ui] Chong Kun Dang's 'Nafabeltan,' being developed as a treatment for COVID-19 in Russia, has shown positive results in the interim evaluation of its Phase 2 clinical trial.

On the 30th, Chong Kun Dang announced, "Russia's Data Safety Monitoring Board (DSMB) conducted an interim evaluation of the safety and efficacy of Nafabeltan's Phase 2 clinical trial and confirmed the clinical usefulness, recommending the continuation of the trial."

The DSMB is a clinical procedure that reviews the safety of subjects and decides whether to continue the trial when 50% of the targeted number of clinical subjects have been enrolled.

In this interim evaluation, Chong Kun Dang administered placebo and Nafabeltan to 50 confirmed COVID-19 patients over 10 days, assessing patient safety along with various clinical indicators.

Chong Kun Dang received approval for Phase 2 clinical trials from the Russian Ministry of Health on August 31 and began patient enrollment on September 25. Enrollment and dosing for all targeted subjects have now been completed. A Chong Kun Dang official explained, "Only the confirmation of the final clinical trial results remains."

The main ingredient of Nafabeltan, Nafamostat, is a substance identified as having potential for development as a COVID-19 treatment through drug repositioning research at the Korea Pasteur Institute.

Based on the DSMB's recommendation, Chong Kun Dang aims to complete the clinical trial within this year and apply for conditional approval in Korea by January next year. On the 20th, it also received approval for Phase 2 clinical trials from the Mexican regulatory authority, expanding its overseas clinical trial countries.

This content was produced with the assistance of AI translation services.